![]()
AccurKardia, an ECG-led diagnostics software company, today announced that it has been named a winner at the 2026 Digital Health & AI Awards, presented by the Digital Health Hub Foundation at HLTH USA 2026 in Las Vegas. AccurKardia is one of three Rising Star winners in the Cardiometabolic, Obesity & Diabetes category. The Foundation selected 38 winners from more than 1,300 participating companies worldwide and announced them on November 16 at its Awards Grand Finale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118557915/en/
AccurKardia CEO Juan Jimenez accepts an award for a Rising Star winner in the Cardiometabolic, Obesity & Diabetes category at the 2026 Digital Health & AI Awards, presented by the Digital Health Hub Foundation at HLTH USA 2026 in Las Vegas. The Foundation selected 38 winners from more than 1,300 participating companies worldwide and announced them on November 16 at its Awards Grand Finale.
The recognition reflects AccurKardia’s mission to transform the ECG into a more powerful diagnostic tool and broad biomarker. AccurECG 2.0, the company’s FDA-cleared software for automated, near real-time ECG interpretation, is cloud-based and device-agnostic, and powers the ECG monitoring products and services of device makers and cardiac monitoring companies at scale. The company’s investigational pipeline aims to move the ECG beyond arrhythmias and help identify disease earlier, in cardiology and beyond. It includes AK-AVS for aortic stenosis and AK+ Guard for hyperkalemia, both of which have received FDA Breakthrough Device Designation.
The award comes in a year in which AccurKardia announced FDA 510(k) clearance and the launch of AccurECG 2.0 and signed various multi-year customer agreements. Research on its investigational algorithms was also presented at the European Society of Cardiology Congress 2026 and the American Heart Association’s Scientific Sessions 2026.
“We thank the Digital Health Hub Foundation and its judges for this recognition. It belongs to our team and to the partners and clinicians who use our technology every day,” said Juan C. Jiménez, co-founder and CEO of AccurKardia. “More than 300 million clinical ECGs are recorded worldwide every year, and the next billion won’t all come from hospitals. Each one needs to be analyzed. Our work is to find the signals that matter, starting with heart rhythm analysis and an investigational pipeline aimed at identifying conditions such as aortic stenosis and hyperkalemia earlier.”
Now in its eighth year, the Digital Health & AI Awards recognize companies transforming healthcare through technology, innovation, and artificial intelligence. With an expanded emphasis on AI in 2026, the awards recognize organizations developing solutions that address pressing challenges in healthcare, improve patient outcomes, and drive change across the healthcare ecosystem.
“Artificial intelligence is fundamentally changing what’s possible in healthcare, and this year’s winners demonstrate how AI and other breakthrough technologies are being translated into meaningful, real-world solutions. Our expanded focus on AI reflects the profound impact these technologies are having across the healthcare ecosystem, from improving patient outcomes to expanding access and transforming care delivery. We are proud to recognize the companies leading this next chapter of healthcare innovation,” said Mark H. Goldstein, chairman of the Digital Health Hub Foundation.
About Digital Health Hub Foundation
The Digital Health Hub Foundation’s mission is to support the world’s most innovative healthcare companies in scaling and growing. Since 2017, its community of more than 30,000 members has been dedicated to fostering innovation, bringing together early-to-late-stage healthcare companies, industry providers, payors, mentors, and investors.
Through the annual Digital Health Hub – Digital Health & AI Awards, the Foundation brings together the healthcare industry to recognize, celebrate, and validate companies advancing the future of health and healthcare.
About AccurKardia
AccurKardia is an ECG-led diagnostics software company focused on transforming ECG data into a more powerful diagnostic tool and broad biomarker to improve patient outcomes and save lives globally. With initial applications in cardiology, the company offers transformative, cloud-based device-agnostic tools, including AccurECG™ 2.0, an FDA-cleared Class II software as a medical device (SaMD) for fully automated, near real-time ECG interpretation. AccurKardia is also advancing an investigational pipeline of ECG-based biomarkers, including AK-AVS™ for aortic stenosis risk assessment and AK+ Guard™ for hyperkalemia risk assessment using Lead I ECG, both of which have received FDA Breakthrough Device Designation. AK+ Guard was awarded the “Best New ECG Technology Solution” in the 10th annual MedTech Breakthrough Awards in 2026. For more information, please visit www.accurkardia.com.
Disclaimers
For detailed technical AccurECG 2.0 requirements, relevant disclosures, and approved indications for use, please refer to the U.S. FDA 510(k) K252361 summary and product labeling.
AK-AVS and AK+ Guard are currently for research use only and have not been cleared or approved by the U.S. FDA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261118557915/en/
Media gallery